PepGen Inc.
Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.
What’s moving PepGen Inc. now
Current reporting with the operating signal separated from the noise.
PepGen Inc. (PEPG) Halts DMD Program After Trial Miss; Shifts Focus to DM1
The story matters when it changes PepGen Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.PepGen Inc. (PEPG) Gets a Buy from Stifel Nicolaus
The story matters when it changes PepGen Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.PepGen Inc. Announces Clinical Hold in the U.S. on IND Application to Initiate a Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)
The story matters when it changes PepGen Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.PepGen Inc. (NASDAQ:PEPG) Q4 2022 Earnings Call Transcript
Investors are testing whether PepGen Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Latest PEPG filings.
Investor-relevant reports are shown first, followed by the company’s other recent official submissions.
PepGen Inc., quarter by quarter.
Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.
First quarter
No verified period-specific item in the current feed.
SEARCH Q1 COVERAGE →Second quarter
No verified period-specific item in the current feed.
SEARCH Q2 COVERAGE →Third quarter
No verified period-specific item in the current feed.
SEARCH Q3 COVERAGE →